CLEVELAND, Ohio— Cleveland-based biotechnology company Discovery Therapeutics Caribe will soon be studying a treatment for diabetic ulcers that was developed in Cuba.
are applied directly to the surface of wounds. However, Heberprot-P is an injection that delivers the active ingredient under the skin, past the chronic wound environment that can otherwise degrade the drug and reduce the effectiveness of the treatment.epidermal growth factor plays a crucial role in the body’s healing process.
Nearly half of patients who undergo lower extremity amputation resulting from diabetic foot ulcers do not survive beyond five years.